| 2.51 0.255 (11.31%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.4  |
1-year : | 3.92 |
| Resists | First : | 2.91 |
Second : | 3.35 |
| Pivot price | 2.75 |
|||
| Supports | First : | 2.2 | Second : | 1.83 |
| MAs | MA(5) : | 2.32 |
MA(20) : | 2.68 |
| MA(100) : | 3.38 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 4.9 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 187.5 | Low : | 2.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BNBX ] has closed above bottom band by 32.9%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.57 - 2.59 | 2.59 - 2.6 |
| Low: | 2.17 - 2.19 | 2.19 - 2.2 |
| Close: | 2.49 - 2.51 | 2.51 - 2.53 |
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
Thu, 18 Dec 2025
BNBX Achieves Milestone with Largest LineaDNA Shipment - GuruFocus
Thu, 18 Dec 2025
Why a 5-gram DNA shipment for cancer testing is worth over $390,000 - Stock Titan
Tue, 09 Dec 2025
BNB Plus Provides BNB Treasury and Operational Updates - Business Wire
Mon, 17 Nov 2025
BNB Plus Corp (NASDAQ: BNBX) rebrand adds DeFi focus, Josh Kruger named chair - Stock Titan
Mon, 17 Nov 2025
Applied DNA Sciences rebrands as BNB Plus, appoints new chairman - Investing.com
Thu, 13 Nov 2025
Applied DNA Sciences Rebrands to BNB Plus Corp. - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 479170 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 264 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.308e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 213.5 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 3.74e+006 % |
| Gross Profit (p.s.) | -209.42 |
| Sales Per Share | -806.18 |
| EBITDA (p.s.) | 7.35294e+006 |
| Qtrly Earnings Growth | -57.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.05 |
| Dividend | 0 |
| Forward Dividend | 94500 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|